Northern Trust Corp Sells 36,038 Shares of Chimerix, Inc. (NASDAQ:CMRX)

Northern Trust Corp trimmed its holdings in shares of Chimerix, Inc. (NASDAQ:CMRX) by 6.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 549,841 shares of the biopharmaceutical company’s stock after selling 36,038 shares during the period. Northern Trust Corp owned approximately 0.61% of Chimerix worth $1,913,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CMRX. Bender Robert & Associates purchased a new position in shares of Chimerix in the 4th quarter worth about $37,000. Susquehanna Fundamental Investments LLC bought a new position in Chimerix in the 4th quarter valued at approximately $59,000. Diadema Partners LP purchased a new stake in Chimerix during the 4th quarter valued at $101,000. Stoneridge Investment Partners LLC increased its holdings in shares of Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 8,134 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new position in Chimerix during the 4th quarter valued at about $183,000. 45.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CMRX. Jefferies Financial Group reissued a “hold” rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. Wall Street Zen assumed coverage on shares of Chimerix in a research report on Sunday, May 18th. They set a “sell” rating for the company. HC Wainwright reaffirmed a “neutral” rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reissued a “neutral” rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Stock Performance

NASDAQ CMRX opened at $8.54 on Tuesday. The stock has a 50 day moving average price of $8.53 and a 200-day moving average price of $5.40. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.55. The company has a market capitalization of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. As a group, equities analysts predict that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.